- Open-label phase III trial enrolling ~500 patients with confirmed stage IV or recurrent EGFR mutated NSCLC progressed on prior EGFR TKI therapy- Efficacy of nivolumab plus chemotherapy, nivolumab plus ipilimumab and chemotherapy alone was compared.- Final result has not been reported. Here, EGFR is linked to non-small cell lung carcinoma.